molecules-logo

Journal Browser

Journal Browser

Special Issue "Glycotherapeutics: Emerging Roles of Glycans in Medicine"

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Chemical Biology".

Deadline for manuscript submissions: closed (30 May 2019).

Special Issue Editor

Prof. Dr. Roland J. Pieters
Website
Guest Editor
Department of Chemical Biology & Drug Discovery, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, PO Box 80082, Utrecht, The Netherlands
Interests: protein-carbohydrate interactions; lectins; glycosidases; carbohydrate microarrays; multivalency; bacterial adhesion; viral adhesion; O-GlcNAcylation
Special Issues and Collections in MDPI journals

Special Issue Information

Dear Colleagues,

Carbohydrates play important roles in nature, and our understanding of them is increasing rapidly. Many recognition processes involving carbohydrates are of importance for proper functioning of biological systems. Similarly, carbohydrate recognition is, in many cases, part of disease. It is natural to expect that compounds affecting protein carbohydrate interactions have therapeutic potential. Thus far, this has only been seen for a select number of striking cases. In this Special Issue we welcome contributions that are involved in interference with disease causing processes. Timely topics in this area include the development of glycomimetics, covalent capture, multivalency, synthetic carbohydrate-based vaccines, antiadhesion of pathogens (viral, bacterial fungal), fluorosugars, iminosugars and others. 

Prof. Dr. Roland J. Pieters
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • protein-carbohydrate interactions
  • inhibitors
  • glucomimetics
  • multivalency
  • bacterial adhesion
  • viral adhesion
  • iminosugars
  • fluorosugars
  • carbohydrate vaccins
  • bacterial toxin inhibition

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Open AccessArticle
Lactosylated Albumin Nanoparticles: Potential Drug Nanovehicles with Selective Targeting Toward an In Vitro Model of Hepatocellular Carcinoma
Molecules 2019, 24(7), 1382; https://doi.org/10.3390/molecules24071382 - 09 Apr 2019
Cited by 4
Abstract
Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs [...] Read more.
Hepatocellular carcinoma (HCC) ranks fifth in occurrence and second in mortality of all cancers. The development of effective therapies for HCC is urgently needed. Anticancer drugs targeted to the liver-specific asialoglycoprotein receptors (ASGPRs) are viewed as a promising potential treatment for HCC. ASGPRs facilitate the recognition and endocytosis of molecules, and possibly vehicles with galactose end groups, by the liver. In this study, bovine serum albumin (BSA) was conjugated with lactose using a thermal treatment. The formation of lactosylated BSA (BSA-Lac) was confirmed by a change of the chemical structure, increased molecular mass, and Ricinus communis lectin recognition. Subsequently, the low-crosslinking BSA-Lac nanoparticles (LC BSA-Lac NPs) and high-crosslinking BSA-Lac nanoparticles (HC BSA-Lac NPs) were synthesized. These nanoparticles presented spherical shapes with a size distribution of 560 ± 18.0 nm and 539 ± 9.0 nm, as well as an estimated surface charge of −26 ± 0.15 mV and −24 ± 0.45 mV, respectively. Both BSA-Lac NPs were selectively recognized by ASGPRs as shown by biorecognition, competition, and inhibition assays using an in vitro model of HCC. This justifies pursuing the strategy of using BSA-Lac NPs as potential drug nanovehicles with selective direction toward hepatocellular carcinoma. Full article
(This article belongs to the Special Issue Glycotherapeutics: Emerging Roles of Glycans in Medicine)
Show Figures

Graphical abstract

Back to TopTop